Updated July 2026 The Ozempic and GLP-1 gastroparesis lawsuits involve claims that manufacturers of GLP-1 medications such as Ozempic, Wegovy, Mounjaro, Rybelsus, Trulicity, Zepbound, and Saxenda failed to adequately warn patients and doctors about the potential risk of developing gastroparesis (i.e., stomach paralysis or delayed gastric emptying), a serious gastrointestinal injury that can cause persistent nausea, vomiting, abdominal pain, bloating, dehydration, malnutrition, hospitalization, or the need for feeding tubes or other invasive treatment
Nobody was interested in his work
How to Choose the Right Option Since compounded semaglutide is no longer legally available as of May 2025, patients should consult healthcare professionals about FDA-approved options like Wegovy, which may now have improved availability and potential cost assistance programs
Grey market retatrutide: what people actually do The "research peptide" label above covers a range of sources, but most retatrutide in circulation comes from a specific supply chain
The two pathways are complementary, not redundant
Among employers with 5,000 or more workers, that figure rose to 43%
